Nurix Therapeutics (NASDAQ:NRIX) Raised to "Hold" at Leerink Partnrs

Leerink Partnrs upgraded shares of Nurix Therapeutics (NASDAQ:NRIX - Free Report) to a hold rating in a research report report published on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Nurix Therapeutics' Q1 2025 earnings at ($0.89) EPS, Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.79) EPS and FY2026 earnings at ($3.32) EPS.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley boosted their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Royal Bank of Canada boosted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Stephens restated an "overweight" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They set an "outperform" rating and a $35.00 price objective on the stock. Finally, HC Wainwright raised their target price on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $30.88.

Remove Ads

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $0.88 during mid-day trading on Monday, hitting $12.99. The stock had a trading volume of 2,288,289 shares, compared to its average volume of 870,393. The firm has a market cap of $985.77 million, a P/E ratio of -4.49 and a beta of 2.18. The business has a 50 day moving average price of $17.00 and a two-hundred day moving average price of $20.77. Nurix Therapeutics has a 1 year low of $11.90 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Equities research analysts predict that Nurix Therapeutics will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. This trade represents a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 in the last ninety days. 7.20% of the stock is owned by insiders.

Institutional Trading of Nurix Therapeutics

Large investors have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock worth $200,349,000 after acquiring an additional 10,047,329 shares during the period. RA Capital Management L.P. acquired a new position in Nurix Therapeutics in the 4th quarter worth approximately $25,120,000. Soleus Capital Management L.P. boosted its stake in shares of Nurix Therapeutics by 97.3% during the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock valued at $39,617,000 after buying an additional 1,036,999 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Nurix Therapeutics during the 4th quarter valued at $16,447,000. Finally, Boxer Capital Management LLC bought a new position in Nurix Therapeutics in the 4th quarter worth $10,608,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.